Intercellular Signaling Peptides and Proteins

Regulatory proteins and peptides that are signaling molecules involved in the process of PARACRINE COMMUNICATION. They are generally considered factors that are expressed by one cell and are responded to by receptors on another nearby cell. They are distinguished from HORMONES in that their actions are local rather than distal.
DrugDrug NameDrug Indication
DB00004Denileukin diftitoxFor treatment of cutaneous T-cell lymphoma
DB00008Peginterferon alfa-2aPeginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies. Peginterferon alfa-2a is also indicated as a monotherapy for adult patients with HBeAg positive and HBeAg negative chronic hepatitis B infection who have compensated liver disease and evidence of viral replication and liver inflammation [FDA Label].
DB00011Interferon alfa-n1For treatment of venereal or genital warts caused by the Human Papiloma Virus
DB00012Darbepoetin alfaFor the treatment of anemia (from renal transplants or certain HIV treatment)
DB00016ErythropoietinIndicated in adult and paediatric patients for the: - treatment of anemia due to Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis. - treatment of anemia due to zidovudine in patients with HIV-infection. - treatment of anemia due to the effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. - reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery.
DB00018Interferon alfa-n3For the intralesional treatment of refractory or recurring external condylomata acuminata.
DB00019PegfilgrastimPegfilgrastim is indicated for use in patients receiving myelosuppressive chemotherapy for non-myeloid malignancies to reduce the incidence of infection. It is also indicated to increase in patients with acute myelosuppresive radiation exposure.
DB00020SargramostimFor the treatment of cancer and bone marrow transplant
DB00022Peginterferon alfa-2bPeginterferon alfa-2b is indicated for the treatment of HCV in combination with [DB00811] and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
DB00026AnakinraFor the treatment of adult rheumatoid arthritis and treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID).
DB00033Interferon gamma-1bInterferon gamma-1b is used for the treatment of Chronic granulomatous disease and Osteopetrosis.
DB00034Interferon Alfa-2a, RecombinantFor the treatment of chronic hepatitis C, hairy cell leukemia, AIDS-related Kaposi's sarcoma, and chronic myelogenous leukemia. Also for the treatment of oral warts arising from HIV infection.
DB00038OprelvekinIndicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia.[Label]
DB00039PaliferminFor treatment of oral mucositis associated with chemotherapy and radiation therapy.
DB00041AldesleukinFor treatment of adults with metastatic renal cell carcinoma.
DB00060Interferon beta-1aFor treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum
DB00068Interferon beta-1bInterferon beta-1b is a drug used for the treatment of relapsing/remitting multiple sclerosis. It has been shown to slow the advance of the disease as well as to decrease the frequency of attacks.
DB00069Interferon alfacon-1For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma
DB00102BecaplerminFor topical treatment of skin ulcers (from diabetes)
DB00105Interferon alfa-2bFor the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma.
DB01277MecaserminFor the long-term treatment of growth failure in pediatric patients with Primary IGFD or with GH gene deletion who have developed neutralizing antibodies to GH [A2322]. It is not indicated to treat Secondary IGFD resulting from GH deficiency, malnutrition, hypothyroidism or other causes; it is not a substitute for GH therapy.
DB05084AbaloparatideInvestigated for use/treatment in postmenopausal osteoporosis to reduce vertebral and/or non-vertebral fractures.
DB05098LeptinInvestigated for use/treatment in lipodystrophy and obesity.
DB05258Interferon alfaInvestigated for use/treatment in hepatitis (viral, C), leukemia (lymphoid), leukemia (myeloid), leukemia (unspecified), and melanoma.
DB05305Cintredekin BesudotoxInvestigated for use/treatment in brain cancer.
DB05332RomiplostimTreatment of chronic immune thrombocytopenic purpura.
DB05344Ciliary neurotrophic factorInvestigated for use/treatment in eye disorders/infections, macular degeneration, and retinal disorders (unspecified).
DB05396Albinterferon Alfa-2BInvestigated for use/treatment in hepatitis (viral, C).
DB05599Fibroblast growth factor-1Investigated for use/treatment in coronary artery disease and peripheral vascular disease.
DB05718Maxy-G34Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics.
DB05934CTCE-0214Investigated for use/treatment in adverse effects (chemotherapy), blood (blood forming organ disorders, unspecified), cancer/tumors (unspecified), neutropenics, and vascular diseases.
DB06138IRL-1620Investigated for use/treatment in cancer/tumors (unspecified).
DB06196IcatibantApproved for use in acute attacks of hereditary angioedema (HAE). Investigated for use/treatment in angioedema, liver disease, and burns and burn infections.
DB06244TraferminInvestigated for use/treatment in coronary artery disease, peripheral vascular disease, periodontal disease, bone fractures, entero-related fistulae, and diabetic foot ulcers.
DB06423EndostatinInvestigated for use/treatment in cancer/tumors (unspecified), macular degeneration, and diabetic retinopathy.
DB06434RepiferminInvestigated for use/treatment in bone marrow transplant, ulcers, and inflammatory bowel disease.
DB06493VelaferminInvestigated for use/treatment in adverse effects (chemotherapy).
DB06534ThrombopoietinInvestigated for use/treatment in thrombocytopenia.
DB06549LabradimilInvestigated for use/treatment in brain cancer and pediatric indications.
DB06562EmfilerminInvestigated for use/treatment in adverse effects (chemotherapy), reproductive health, and infertility.
DB09046MetreleptinMetreleptin is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
DB09103AncestimAncestim, in combination with filgrastim, is indicated for the setting of autologous peripheral blood progenitor cell transplantation in patients at risk of poor peripheral blood progenitor cell mobilisation.[L1090] The use of ancestim with filgrastim will generate a sustained increase in the number of peripheral blood progenitor cells capable of engraftment. It is used for mobilization of progenitor cells from the bone marrow to the peripheral blood with or withouth mobilizing chemotherapy. The harvested progenitor cells can be used for transplant following myelosuppressive or myeloablative therapies.[L1089]
DB09107Methoxy polyethylene glycol-epoetin betaFor the treatment of patients with anaemia associated with chronic kidney disease. Not a substitute for RBC transfusion if immediate correction of anemia is required.
DB09122Peginterferon beta-1aFor the treatment of patients with relapsing forms of multiple sclerosis.
DB11624Epoetin deltaNot Available
DB11631Eptotermin AlfaNot Available
DB11639Dibotermin alfa- indicated for the treatment of acute tibia fractures in adults, as an adjunct to standard care using open fracture reduction and intramedullary unreamed nail fixation [FDA Label]. - indicated for single-level lumbar interbody spine fusion as a substitute for autogenous bone graft in adults with degenerative disc disease who have had at least 6 months of non-operative treatment for this condition [L1391].
DB11955AvoterminNot Available
DB11975TAK-448Not Available
DB11997Interleukin-7Not Available
DB12075NagrestipenNot Available
DB12126BradykininNot Available
DB12182BinetrakinNot Available
DB12349DulanerminNot Available
DB12431MuplestimNot Available
DB12525MolgramostimNot Available
DB12616SpriferminNot Available
DB12620Nerve Growth FactorNot Available
DB12652Endothelin-1Not Available
DB12699BalugrastimNot Available
DB12880Interleukin-10Not Available
DB13144LenograstimThe drug is used to reduce the risk of life-threatening infection in patients with neutropenia, particularly after cytotoxic chemotherapy. Lenograstim is indicated as a treatment to reduce the duration of neutropenia and the severity of infections in patients with non-myeloid malignancy who have undergone autologous or allogeneic bone marrow transplantation, or treatment with established cytotoxic chemotherapy and in addition to reduce the incidence of infection associated with established cytotoxic chemotherapy. Lenograstim is also indicated to mobilise peripheral blood progenitor cells (PBPCs) with Lenograstim alone, or after myelosuppressive chemotherapy, in order to accelerate haematopoietic recovery by infusion of such cells, after myelosuppressive or myeloablative therapy. Lenograstim is also indicated to accelerate the engraftment of these cells after their reinfusion. GRANOCYTE is also indicated for the treatment of severe chronic neutropenia including congenital agranulocytosis (Kostmann's syndrome).
DB13200LipegfilgrastimIndicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) [L2441].
DB14076Interleukin-1 alpha, human recombinantNot Available
DB14131Basic Fibroblast Growth FactorBasic Fibroblast Growth Factor is not currently approved for any FDA or Health Canada approved indications.
DB14145NepiderminNot Available
DB14472Insulin-like growth factor IINot Available
DB06651DiaPep 277Investigated for use/treatment in diabetes mellitus type 1, autoimmune diseases, and diabetes mellitus type 2.
DB05386RegramostimInvestigated for use/treatment in adverse effects (chemotherapy) and bone marrow transplant.
DB05875Sar9, Met (O2)11-Substance PInvestigated for use/treatment in acute respiratory distress syndrome (ARDS) and viral infection.
DB14767Peginterferon lambda-1aNot Available
DB14865Human interleukin-2Not Available
DB14999Human interferon betaNot Available
DB15015Recombinant CD40-ligandNot Available
DB15095LeridistimNot Available
DB15131Interferon alfa-2cNot Available
DB15386ALT-801Not Available
DB15389TeceleukinNot Available
DB15402Tucotuzumab celmoleukinNot Available
DB15443Lorukafusp alfaNot Available
DrugDrug NameTargetType
DB00004Denileukin diftitoxInterleukin-2 receptor subunit alphatarget
DB00004Denileukin diftitoxCytokine receptor common subunit gammatarget
DB00004Denileukin diftitoxInterleukin-2 receptor subunit betatarget
DB00008Peginterferon alfa-2aInterferon alpha/beta receptor 2target
DB00008Peginterferon alfa-2aInterferon alpha/beta receptor 1target
DB00008Peginterferon alfa-2aCytochrome P450 1A2enzyme
DB00011Interferon alfa-n1Interferon alpha/beta receptor 2target
DB00011Interferon alfa-n1Interferon alpha/beta receptor 1target
DB00012Darbepoetin alfaErythropoietin receptortarget
DB00016ErythropoietinErythropoietin receptortarget
DB00018Interferon alfa-n3Interferon alpha/beta receptor 1target
DB00018Interferon alfa-n3Interferon alpha/beta receptor 2target
DB00019PegfilgrastimGranulocyte colony-stimulating factor receptortarget
DB00019PegfilgrastimNeutrophil elastasetarget
DB00020SargramostimGranulocyte-macrophage colony-stimulating factor receptor subunit alphatarget
DB00020SargramostimBone marrow proteoglycantarget
DB00020SargramostimInterleukin-3 receptor subunit alphatarget
DB00020SargramostimCytokine receptor common subunit betatarget
DB00020SargramostimSyndecan-2target
DB00022Peginterferon alfa-2bInterferon alpha/beta receptor 1target
DB00022Peginterferon alfa-2bInterferon alpha/beta receptor 2target
DB00022Peginterferon alfa-2bCytochrome P450 1A2enzyme
DB00022Peginterferon alfa-2bCytochrome P450 2D6enzyme
DB00022Peginterferon alfa-2bCytochrome P450 2C9enzyme
DB00026AnakinraInterleukin-1 receptor type 1target
DB00033Interferon gamma-1bInterferon gamma receptor 1target
DB00033Interferon gamma-1bInterferon gamma receptor 2target
DB00034Interferon Alfa-2a, RecombinantInterferon alpha/beta receptor 1target
DB00034Interferon Alfa-2a, RecombinantInterferon alpha/beta receptor 2target
DB00038OprelvekinInterleukin-11 receptor subunit alphatarget
DB00039PaliferminFibroblast growth factor receptor 2target
DB00039PaliferminNeuropilin-1target
DB00039PaliferminFibroblast growth factor receptor 1target
DB00039PaliferminFibroblast growth factor receptor 4target
DB00039PaliferminFibroblast growth factor receptor 3target
DB00039PaliferminBasement membrane-specific heparan sulfate proteoglycan core proteintarget
DB00041AldesleukinInterleukin-2 receptor subunit betatarget
DB00041AldesleukinInterleukin-2 receptor subunit alphatarget
DB00041AldesleukinCytokine receptor common subunit gammatarget
DB00041AldesleukinProstaglandin G/H synthase 2enzyme
DB00041AldesleukinCytosolic phospholipase A2enzyme
DB00041AldesleukinCytochrome P450 3A4enzyme
DB00041AldesleukinXanthine dehydrogenase/oxidaseenzyme
DB00041AldesleukinCytochrome P450 2E1enzyme
DB00060Interferon beta-1aInterferon alpha/beta receptor 1target
DB00060Interferon beta-1aInterferon alpha/beta receptor 2target
DB00068Interferon beta-1bInterferon alpha/beta receptor 1target
DB00068Interferon beta-1bInterferon alpha/beta receptor 2target
DB00069Interferon alfacon-1Interferon alpha/beta receptor 1target
DB00069Interferon alfacon-1Interferon alpha/beta receptor 2target
DB00102BecaplerminPlatelet-derived growth factor receptor betatarget
DB00102BecaplerminAlpha-2-macroglobulintarget
DB00102BecaplerminPlatelet-derived growth factor receptor alphatarget
DB00105Interferon alfa-2bInterferon alpha/beta receptor 2target
DB00105Interferon alfa-2bInterferon alpha/beta receptor 1target
DB00105Interferon alfa-2bCytochrome P450 1A2enzyme
DB01277MecaserminInsulin-like growth factor 1 receptortarget
DB01277MecaserminInsulin-like growth factor-binding protein 3target
DB01277MecaserminInsulin receptortarget
DB01277MecaserminCation-independent mannose-6-phosphate receptortarget
DB01277MecaserminInsulin-like growth factor-binding protein 3carrier
DB01277MecaserminInsulin-like growth factor-binding protein complex acid labile subunitcarrier
DB01277MecaserminInsulin-like growth factor-binding protein 1carrier
DB01277MecaserminInsulin-like growth factor-binding protein 2carrier
DB01277MecaserminInsulin-like growth factor-binding protein 4carrier
DB01277MecaserminInsulin-like growth factor-binding protein 5carrier
DB01277MecaserminInsulin-like growth factor-binding protein 6carrier
DB05084AbaloparatideParathyroid hormone/parathyroid hormone-related peptide receptortarget
DB05098LeptinLeptin receptortarget
DB05258Interferon alfaInterferon alpha/beta receptor 1target
DB05305Cintredekin BesudotoxInterleukin-13target
DB05332RomiplostimThrombopoietin receptortarget
DB05934CTCE-0214Stromal cell-derived factor 1target
DB06138IRL-1620Endothelin B receptortarget
DB06196IcatibantB2 bradykinin receptortarget
DB06196IcatibantAminopeptidase Ntarget
DB06423Endostatin72 kDa type IV collagenasetarget
DB06423EndostatinMatrix metalloproteinase-9target
DB06423EndostatinCollagenase 3target
DB06423EndostatinFocal adhesion kinase 1target
DB06423EndostatinE-selectintarget
DB06423EndostatinCytochrome P450 19A1enzyme
DB06534ThrombopoietinThrombopoietin receptortarget
DB06549LabradimilB2 bradykinin receptortarget
DB09046MetreleptinLeptin receptortarget
DB09103AncestimMast/stem cell growth factor receptor Kittarget
DB09107Methoxy polyethylene glycol-epoetin betaErythropoietin receptortarget
DB11639Dibotermin alfaBone morphogenetic protein receptor type-1Atarget
DB11639Dibotermin alfaBone morphogenetic protein receptor type-2target
DB13144LenograstimGranulocyte colony-stimulating factor receptortarget
DB13200LipegfilgrastimGranulocyte colony-stimulating factor receptortarget
DB05386RegramostimGranulocyte-macrophage colony-stimulating factor receptor subunit alphatarget
DB05386RegramostimGM-CSF receptor alpha subunittarget
DB05386RegramostimCholinesteraseenzyme
DB05875Sar9, Met (O2)11-Substance PCytochrome P450 19A1enzyme
DB05875Sar9, Met (O2)11-Substance PCholinesteraseenzyme
DB05875Sar9, Met (O2)11-Substance PProstaglandin G/H synthase 2enzyme